1RV Stoklara Genel Bakış Ticari aşamada bir biyofarmasötik şirketi olan Rhythm Pharmaceuticals, Inc. nadir görülen nöroendokrin hastalıklara odaklanmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Rhythm Pharmaceuticals, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Rhythm Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$57.50 52 Haftanın En Yüksek Seviyesi US$62.50 52 Haftanın En Düşük Seviyesi US$32.20 Beta 2.17 1 Aylık Değişim 4.55% 3 Aylık Değişim 27.78% 1 Yıllık Değişim 52.12% 3 Yıllık Değişim 592.77% 5 Yıllık Değişim 193.37% Halka arzdan bu yana değişim 165.14%
Son Haberler & Güncellemeler
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05 Daha fazla güncelleme görün
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05
Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 23
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old Aug 26
Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023) Aug 07
Forecast to breakeven in 2026 Aug 07
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old Jul 31 Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer Jul 08
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index Jul 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome Jun 29
New minor risk - Profitability May 09
No longer forecast to breakeven May 08
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 08
First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023) May 07
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology Apr 30
Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 26
New major risk - Financial position Apr 04
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 03 Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 02
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist Mar 27 Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals Mar 21
Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022) Feb 23
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan Feb 23
New minor risk - Profitability Feb 09
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Feb 07
Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 01
New major risk - Share price stability Jan 23
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022) Nov 09
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) Nov 03
Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome Sep 07
Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022) Aug 02
Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 18
Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 Jun 19
Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients May 09
First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021) Mar 02
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome Jan 24
Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Nov 22
Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021) Nov 09
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology Nov 09
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023 Nov 03
Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA Nov 02
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development Oct 07
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022 Sep 20
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide) Sep 07
Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021) Aug 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome Jul 23
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France Jul 21
NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency Jul 19
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity Jul 13
Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment Jun 23
Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome Jun 17
Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022 Jun 14
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting May 04
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity Apr 07
Forecast to breakeven in 2024 Feb 26
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome Feb 25 Rhythm Pharmaceuticals, Inc. Announces Executive Promotions
Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS) Feb 17 Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder
High number of new directors Nov 04
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain Sep 23
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes Sep 21
Chief Medical Officer Murray Stewart has left the company Sep 15
Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Sep 10
Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity Aug 05
Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE Jul 25 Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index
Independent Director Todd Foley has left the company Jun 15
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency May 22
Chief Human Resources Officer has left the company May 01
Chairman recently bought €172k worth of stock Apr 01
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss At Up to Nine Months in Patients with Het Obesity on Setmelanotide At Endo 2021 Mar 21
Rhythm Pharmaceuticals, Inc. Announces Board Changes Mar 17
New 90-day low: €20.80 Mar 06
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities Jan 29
New 90-day high: €31.20 Jan 23
New 90-day high: €26.80 Jan 07
Rhythm Pharmaceuticals, Inc. Announces Committee Appointments Jan 05 Hissedar Getirileri 1RV DE Biotechs DE Pazar 7D 6.5% 2.5% -0.4% 1Y 52.1% -10.2% 7.9%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 1RV geçen yıl % -10.2 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: 1RV geçen yıl % 7.9 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is 1RV's price volatile compared to industry and market? 1RV volatility 1RV Average Weekly Movement 8.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 1RV hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 1RV 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Kuruldu Çalışanlar CEO Web sitesi 2008 226 David Meeker rhythmtx.com
Ticari aşamada bir biyofarmasötik şirketi olan Rhythm Pharmaceuticals, Inc. nadir görülen nöroendokrin hastalıklara odaklanmaktadır. Şirketin öncü ürün adayı, pro-opiomelanokortin (POMC), proprotein konvertaz subtilisin/keksin tip 1, leptin reseptörü (LEPR) eksikliği obezitesi ve Bardet-Biedl ve Alström sendromunun tedavisi için nadir bir melanokortin-4 reseptörü olan IMCIVREE'dir (setmelanotid). POMC veya LEPR heterozigot eksikliği obeziteleri, steroid reseptör koaktivatör 1 eksikliği obezitesi, SH2B1 eksikliği obezitesi, MC4 reseptör eksikliği obezitesi ve diğer MC4R bozukluklarının tedavisi için Faz 3 klinik çalışmalarındadır.
Daha fazla göster Rhythm Pharmaceuticals, Inc. Temel Bilgiler Özeti Rhythm Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 1RV temel i̇stati̇sti̇kler Piyasa değeri €3.56b Kazançlar(TTM ) -€253.83m Gelir(TTM ) €109.20m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 1RV gelir tablosu (TTM ) Gelir US$112.53m Gelir Maliyeti US$12.81m Brüt Kâr US$99.72m Diğer Giderler US$361.29m Kazançlar -US$261.57m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -4.26 Brüt Marj 88.61% Net Kâr Marjı -232.45% Borç/Özkaynak Oranı 71.5%
1RV uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/05 15:01 Gün Sonu Hisse Fiyatı 2025/01/03 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Rhythm Pharmaceuticals, Inc. 18 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Tazeen Ahmad BofA Global Research Whitney Ijem Canaccord Genuity Corinne Johnson Goldman Sachs
Göster 15 daha fazla analist 
